Keros-Takeda license for elritercept effective; $200M upfront payment triggered

Keros Therapeutics, Inc.

Global license agreement with Takeda (TSE:4502/NYSE:TAK) for elritercept became effective Jan 16, 2025.
Upfront payment of $200.0 million from Takeda to Keros was triggered upon effectiveness.
Agreement was previously announced on Dec 3, 2024; effectiveness followed HSR waiting period expiration.
Elritercept is a clinical-stage therapy targeting TGF-ß family signaling disorders.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.